Ottobock SE & Co. KGaA, the global MedTech company listed on the stock exchange, has appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board effective 22 June 2026. She succeeds Stefan Heidenreich, whose regular five-year term on the Management Board has concluded. This change comes as the company continues to strengthen its leadership in the medical technology sector.
Professor Hans Georg Nader, Chairman of the Management Board of Ottobock SE & Co. KGaA, highlighted the significance of the appointment: "With Dr. Katarzyna Mazur-Hofsaess, we are gaining a proven expert in international medical technology and healthcare. Her experience in global companies and her medical background will be a valuable addition to our Board." Dr. Mazur-Hofsaess brings extensive international experience, having served on the Management Board of Fresenius Medical Care from 2018 to 2025 and as CEO of its MedTech segment Care Enablement. Prior to that, she led the EMEA region at Zimmer Biomet, a US-based specialist in joint replacement solutions. Earlier in her career, she held positions at Abbott Diagnostics and Roche Polska. She is also currently an independent, non-executive Director at Smith & Nephew.
A physician by training, Dr. Mazur-Hofsaess earned her doctorate at the Medical University of Gdansk and completed management studies at the Warsaw School of Economics and the University of Minnesota. Her career began at the University Clinical Centre in Gdansk.
Stefan Heidenreich stepped down after his five-year term, having served as Deputy Chairman of the Management Board and playing a key role in Ottobock's strategic development. The company expressed its gratitude for his contributions, particularly in guiding Ottobock's transition to a listed company. For more information, see the original release on NewMediaWire.
This leadership change underscores Ottobock's commitment to innovation and global growth. The company, known for its prosthetics, neuro-orthotics, and exoskeletons, operates in 45 countries and runs the world's largest international patient care network with around 420 centers. With over 2,600 patents and a strong R&D focus, Ottobock is shaping the future of Human Bionics. The appointment of Dr. Mazur-Hofsaess is expected to drive further advancements in the company's mission to improve freedom of movement and quality of life for people with limited mobility.
